AxoGen (NASDAQ: AXGN) is one of 46 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare AxoGen to related businesses based on the strength of its dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.
Volatility & Risk
AxoGen has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, AxoGen’s rivals have a beta of 1.58, meaning that their average stock price is 58% more volatile than the S&P 500.
This table compares AxoGen and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AxoGen||$60.43 million||-$10.44 million||-123.87|
|AxoGen Competitors||$1.10 billion||$121.87 million||-38.29|
AxoGen’s rivals have higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares AxoGen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
67.8% of AxoGen shares are owned by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 7.9% of AxoGen shares are owned by company insiders. Comparatively, 20.1% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for AxoGen and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AxoGen presently has a consensus price target of $33.14, indicating a potential downside of 13.69%. As a group, “Electromedical equipment” companies have a potential upside of 21.16%. Given AxoGen’s rivals higher possible upside, analysts clearly believe AxoGen has less favorable growth aspects than its rivals.
AxoGen rivals beat AxoGen on 9 of the 13 factors compared.
AxoGen Company Profile
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.